APVO
Aptevo Therapeutics Inc.Company with tickers: APVO
CIK
1671584
CUSIP
03835L702
Shares Outstanding
1,246,105
Website
https://aptevotherapeutics.com
Investor Relations
https://aptevotherapeutics.com/investors-sample/
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $3,924,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Operating Income | $-6,837,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Net Income | $-6,697,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Basic) | $-6.41 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Diluted) | $-6.41 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |